// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

IMMU-40. SINGLE-CELL LEVEL COMPARISON OF HISTOPATHOLOGY AND SINGLE-CELL RNA-SEQ DATABASES BETWEEN IDH-MUT AND –WT GLIOBLASTOMAS REVEALS DISTINCT INNATE IMMUNE MICROENVIRONMENTS THAT CAN BE EXPLOITED FOR THERAPEUTIC GAIN

Candice Poon - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Interleukin-10

GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES

Sheila Mansouri - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?

Vijay Ramaswamy - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY

Craig Horbinski - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

GENE-37. ATRX INACTIVATION DISRUPTS GLOBAL HETEROCHROMATIN LANDSCAPES AND ALTERS DISEASE-RELEVANT TRANSCRIPTIONAL ACTIVITY

Carla Danussi - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

GENE-26. MOLECULAR CHARACTERIZATION OF BENIGN AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS THAT OCCUR IN SPORADIC AND SYNDROMIC SETTINGS

Suganth Suppiah - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

EXTH-28. ENHANCING SELUMETINIB-MEDIATED KILLING OF SHH MEDULLOBLASTOMA

Brent Guppy - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

selumetinib

EXTH-74. MOLECULAR MECHANISMS OF ANTI-TUMOR ACTION OF TTFIELDS DETERMINED BY MEASUREMENTS AND MODELING OF ELECTRO-CONDUCTIVE PROPERTIES OF MICROTUBULES

Jack Tuszynski - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

EXTH-25. DIANHYDROGALACTITOL (VAL-083) REDUCES GLIOBLASTOMA TUMOR GROWTH IN VIVO, UPON BEVACIZUMAB-INDUCED HYPOXIA

Anna Golebiewska - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dianhydrogalactitol

EXTH-09. DIANHYDROGALACTITOL (VAL-083) HAS THE POTENTIAL TO OVERCOME MAJOR CHALLENGES IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Anne Steino - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dianhydrogalactitol

EPID-18. MALIGNANT PRIMARY BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMOURS DIAGNOSED AMONG THE CANADIAN POPULATION FROM 2009 TO 2013

Emily Walker - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

EPID-16. CONSIDERATIONS FOR A SURGICAL RCT IN LOW-GRADE GLIOMAS: A SURVEY

Alireza Mansouri - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxyzine

DRES-04. CHARACTERIZATION OF A MODEL OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA

Elizabeth Bering - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Temozolomide

DRES-09. IN VIVO FUNCTIONAL GENOMICS IDENTIFIES DRIVERS OF CHEMORESISTANCE IN MEDULLOBLASTOMA

Ana Guerreiro Stücklin - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

DRES-06. PREVENTING THE EMERGENCE OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA BY PARP-1 INHIBITION

Alice Yuan - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Temozolomide

COMP-06. GLIOBLASTOMA DEVELOPMENT MIRRORS THE DEVELOPING BRAIN

Jack Antel - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

CSIG-02. VAL-083 INHIBITS PROLIFERATION OF A PANEL OF EIGHT GLIOBLASTOMA STEM CELL LINES: DOWNREGULATION OF BDR4 AS A NOVEL ANTI-NEOPLASTIC MECHANISM

Elise Fernandez - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dianhydrogalactitol

CSIG-14. ALPHA-CARDIAC ACTIN 1 IS EXPRESSED IN MEDULLOBLASTOMA AND MAY PLAY A ROLE IN CELL SURVIVAL DURING MITOTIC INHIBITION

Rahul Suresh - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

CSIG-06. THE MOLECULAR SUBTYPE OF PRIMARY GLIOBLASTOMA CELLS CORRELATES WITH RESPONSE TO THERAPEUTIC AGENTS THAT INDUCE APOPTOSIS OR SENESCENCE

Ritesh Kumar - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

triapine

CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS

Romina Nejad - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved